Bio-Rad Laboratories (BIO) EBT Margin (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported EBT Margin for 18 consecutive years, with 83.27% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT Margin rose 1974.0% year-over-year to 83.27% in Q2 2026; TTM through Jun 2026 was 13.53%, a 409.0% decrease from a year earlier, with the FY2025 full-year figure at 38.54%, up 12981.0% from the prior year.
• EBT Margin was 83.27% for Q2 2026 at Bio-Rad Laboratories, up from 116.5% in the prior quarter.
• Over five years, EBT Margin peaked at 149.45% in Q4 2022 and troughed at 623.92% in Q1 2022.
• A 5-year average of 58.42% and a median of 13.39% in 2023 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin sank 80240 bps in 2022 and surged 63645 bps in 2023, its largest moves.
• Over 5 years, EBT Margin stood at 149.45% in 2022, then slumped by 58 bps to 62.89% in 2023, then slumped by 317 bps to 136.16% in 2024, then soared by 198 bps to 134.05% in 2025, then tumbled by 38 bps to 83.27% in 2026.
• The last three EBT Margin figures came in at 83.27% (Q2 2026), 116.5% (Q1 2026), and 134.05% (Q4 2025), per Business Quant data.